Aura Biosciences, Inc. is a clinical-stage biotechnology company that develops targeted oncology therapies using its proprietary Virus-Like Drug Conjugate (VDC) technology. The company's platform uses virus-like particles conjugated with drugs or loaded with nucleic acids to selectively attack tumor cells while sparing healthy tissue. Aura's lead product candidate, belzupacap sarotalocan (bel-sar), is currently in late-stage clinical trials for the first-line treatment of early-stage choroidal melanoma, a rare eye cancer. Additionally, the company is expanding its pipeline to evaluate bel-sar in other solid tumors, including choroidal metastasis and non-muscle invasive bladder cancer. Headquartered in Boston, Massachusetts, Aura aims to provide vision- and organ-preserving therapies for cancer patients with high unmet medical needs.
